North America Market Research Reports & Industry Analysis

Publications found: 97,050
Sort by:

Analyzing the Tobacco Industry in Canada

US$ 320.00

... . Aruvians Rsearch analyzes the Canadian tobacco industry in its research offering Analyzing the Tobacco Industry in Canada. The report is an in-depth profile of the tobacco industry in Canada as well as the ...

March 2012 75 pages

Analyzing the Tobacco Industry in Mexico

US$ 320.00

... . Aruvians Rsearch analyzes the Mexican tobacco industry in its research offering Analyzing the Tobacco Industry in Mexico. The report is an in-depth profile of the tobacco industry in Mexico as well as the ...

March 2012 75 pages

Analyzing the Tobacco Industry in United States

US$ 320.00

The tobacco market in the United States has been growing slowly in recent years and the trend is ... company market share. Future of the global tobacco industry is also analyzed. For the US tobacco industry, we analyze the tobacco market through an industry overview, industry value ...

March 2012 90 pages

Analyzing Major Household Appliances Industry in US

US$ 300.00

... by LG Electronics and Samsung Electronics. Aruvians Rsearch analyzes the major household appliances in the US industry in its research offering Analyzing Major Household Appliances Industry in US. The report is a complete analysis of the ...

March 2012 70 pages

Analyzing Pesticides Industry in United States

US$ 350.00

... , SePRO, Zep and others. Aruvians Rsearch analyzes the pesticides industry in the US in its research offering Analyzing Pesticides Industry in United States. The report is a complete analysis of the ...

March 2012 135 pages

Analyzing Power Tools Market in United States

US$ 350.00

... Analyzing Power Tools Market in United States. The report is a complete analysis of the industry through the leading segments of electric tools, pneumatic tools, engine-driven tools, and other power tools. The report analyzes ...

March 2012 90 pages

Bristol-Myers Squibb - Eliquis: FDA Decision Date Extended by Three Months

US$ 90.00

... BMY, the USFDA has extended the review period for Eliquis by 3 months (new PDUFA June 28th). At this ... has not announced any advisory committee to discuss Eliquis approval, but one may not rule out ... concerns over safety of Dabigatran. This delay in Eliquis approval, will obviously give some additional time for ...

February 2012 2 pages

INCYTE: Testing Time Ahead For JAKAFI

US$ 140.00

While the commercial challenge for Incyte (INCY) in US has just begun (reported only $2m net sales since ... , please read our report released on February 28, 2012 on INCY, titled “Testing Time Ahead For JAKAFI”.

February 2012 3 pages

VIVUS: Potential for Adding More Weight in April

US$ 140.00

... safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, ... approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”

February 2012 9 pages

REGENERON: Marching Towards Profitability!

US$ 140.00

... Lucentis)! REGN should finally evolve from a Rising Star to become a profitable Biotech from 2012 onwards on the strength of its pipeline and ... , please read our report released on February 17, 2012 on REGN, titled “Marching Towards Profitability!”

February 2012 8 pages

Future US Tumor Marker Testing Market Outlook

US$ 6,960.00

... leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ... base of automated and semi-automated analyzers used for tumor marker testing. Current instrumentation technologies and feature comparison of leading analyzers. ...

February 2012 620 pages

Future US Nucleic Acid Testing Market Outlook

US$ 6,720.00

... comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing ...

February 2012 880 pages

ALEXION: Orphan Drugs and Innovative Biologics = Irresistible Combination!

US$ 140.00

... beyond soliris and experience in developing and marketing orphan drugs should increase its value beyond Genzyme… For more ... on February 15, 2012 on ALXN, titled “Orphan Drugs and Innovative Biologics = Irresistible Combination!”. Key words: Alexion, Acute Hormonal Rejection , Atypical Hemolytic Uremic ...

February 2012 6 pages

VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!

US$ 140.00

... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...

February 2012 12 pages

Future US Microbiology Testing Market Outlook

US$ 7,520.00

Highlights Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...

February 2012 1037 pages

Future US Transfusion Diagnostic Testing Market Outlook

US$ 7,120.00

Highlights Comprehensive 460-pages market segmentation analysis of the US transfusion testing market. Major issues pertaining to the US transfusion testing practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

February 2012 460 pages

CELGENE - Core Business + Pipeline Investments = Long Term Growth

US$ 140.00

Celgene (CELG) reported robust FY11 earnings, despite weak economies and ... detail, please read our report released on 10th Feb., 2012 on Celgene titled “CELGENE - Core Business + Pipeline Investments = Long Term Growth”.

February 2012 9 pages

GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!

US$ 140.00

Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”

February 2012 11 pages

AMGEN - Still Worth Holding!

US$ 90.00

Amgen (AMGN) has sufficient cash (total cash: $19.6b, Lt. Debt: $21.4b) and experience to ... -up, it is still trading at a favorable multiple against its peers. For more details, please read our report released on 9th Feb., 2012 titled “Still worth Holding!”

February 2012 7 pages

BIOGEN IDEC - Investing for Long-Term

US$ 140.00

Biogen Idec (BIIB) promises to enrich its revenue stream and MS franchise in 2012 ... detail, please read our report released on 8th Feb., 2012 on Biogen Idec titled “Investing for Long-Term”.

February 2012 9 pages

MERCK - Vorapaxar: Subgroup Analyses Hold the Key: TRA-2P study Met Primary Endpoint

US$ 90.00

Merck today announced the topline results from much awaited Vorapaxar clinical study in secondary prevention of heart attack and stroke (TRA-2P). Addition of Vorapaxar to standard ... TRA-2P with external experts to help better understand the profile of Vorapaxar in specific patient populations.

February 2012 2 pages

Canada’s Biotechnology Industry - Porter’s Five Forces Strategy Analysis

US$ 175.00

... is a critical element of national power. Advances in biotechnology are resulting in novel biomedical and pharmaceutical products and processes ... the world’s citizens. Aruvian's R'search analyzes the Canadian Biotechnology industry in the Michael Porter’s Five Forces Analysis. It uses concepts developed in ...

February 2012 20 pages

Drug Industry in the United States - Porter’s Five Forces Strategy Analysis

US$ 175.00

... falling, leading to layoffs and cuts in research budgets. While the US drug industry is hardly in a full-blown crisis, however, layoffs are occurring ... taken once a week instead of daily. Aruvian's R'search analyzes the United States Drug Industry in the Michael Porter’s Five Forces Analysis. It uses concepts ...

February 2012 12 pages

Analyzing the Chemical Industry in United States

US$ 375.00

... the environment. Aruvian's R'search’s report Analyzing the Chemical Industry in United States researches the characteristics of the US chemical industry and the segments which, as a ... the reputation and pride for the US Chemical Industry globally and placing the United States at the top of the pecking order ...

February 2012 250 pages

Construction Industry in Canada – Porter’s Five Forces Strategy Analysis

US$ 175.00

... domestic market and is extremely fragmented. Aruvian's R'search analyzes The Construction Industry in Canada in Michael Porter’s Five Forces Analysis. It uses concepts developed ...

February 2012 20 pages

Footwear Industry in Canada – Porter’s Five Forces Strategy Analysis

US$ 175.00

... . There is a need to provide innovative solutions in the Canadian Footwear Industry to remain competitive and retain customers. Manufacturers have to make ... lower the product development costs. Aruvian's R'search analyzes The Footwear Industry in Canada in Michael Porter’s Five Forces Analysis. It uses concepts ...

February 2012 20 pages

Food Processing in Canada – PEST Framework Analysis

US$ 175.00

The largest food processing industry, measured by shipments and value added, in Canada was meat processing. The sugar and confectionery ... by grain and oilseed milling (10%), fruit and vegetable processing (9%). Aruvian's R'search analyzes Food Processing in Canada in a PEST Framework Analysis. A PEST analysis ...

February 2012 20 pages

Cosmetics Industry in Canada – Porter’s Five Forces Strategy Analysis

US$ 175.00

The cosmetics and toiletries industry in Canada continues to benefit from a combination of strong macroeconomic trends and key ... to changing circumstances remain vital to success. Aruvian's R'search analyzes The Cosmetics Industry in Canada in Michael Porter’s Five Forces Analysis. It uses concepts developed ...

February 2012 20 pages

Canada’s Life Insurance Industry – PEST Framework Analysis

US$ 175.00

... future. Traditional insurance, such as life and health, spreads risk across many persons to insure against loss of life, serious disability ... or the need for additional medical attention. Aruvian's R'search analyzes Canada’s Life Insurance Industry in a PEST Framework Analysis. A PEST analysis is concerned ...

February 2012 20 pages

Canada’s Life Insurance Industry – Porter’s Five Forces Strategy Analysis

US$ 175.00

... for flexible and tax-efficient products. Aruvian's R'search analyzes Canada’s Life Insurance Industry in Michael Porter’s Five Forces Analysis. It uses concepts developed ...

February 2012 25 pages

Pharmaceutical Industry in Mexico

US$ 325.00

... cellular and molecular levels to dramatically advance the treatment of disease. Mexico’s pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development ...

February 2012 120 pages

Analyzing the US Cosmeceuticals Industry

US$ 300.00

... and rule. Aruvians Rsearch analyzes the US Cosmeceutical Industry in its research offering Analyzing the US Cosmeceuticals Industry. The report ... The various cosmeceuticals analyzed include hair care cosmeceuticals, skin care cosmeceuticals, injectable cosmeceuticals and other cosmeceuticals. Product ...

February 2012 80 pages

Novo Nordisk and Amylin - Bydureon Approval in the US - A Positive signal for the class

US$ 140.00

... current marketed GLP-1’s. We forecast $3billion in peak sales for the Amylin’s GLP-1 franchise (Byetta, Bydureon and once monthly exenatide suspension ... is expected to reach the market beyond 2013, and will help Amylin further build its dominance in the GLP-1 space.

January 2012 10 pages

BMY 4Q-11 Results – Patent expiry pains reflecting in the guidance

US$ 90.00

Post today’s announcement of 4Q-11 results, we reiterate our underperform rating on BMY with a PT of $26. The 2012 EPS guidance range of $1.9 - $2.0 is ... reflective of the towering pressures, while valuation continues to remain soaring. BMY holds a promising HCV pipeline, but seems priced to perfection. Yeryoy ...

January 2012 1 pages

Halozyme – “Offers Convenience Benefit but Commercial Success Uncertain”

US$ 140.00

We have initiated coverage on Halozyme (HALO) after analyzing its risk reward opportunity. At first flush ... details, please read our report released on 27th January, 2012 on Halozyme titled “Offers Convenience Benefit but Commercial Success Uncertain”

January 2012 8 pages

American Directory of Education Foundations 2012

US$ 195.00

PDF version is dispatched within twenty-four hours after the purchase. PDF option available starting May, 20 This new directory of education foundations, trusts, and grant-making NGO’s and other simil...

January 2012 -

USA Biotechnology Directory 2012 - 2013

US$ 200.00

PDF version is dispatched within twenty-four hours after the purchase. The most comprehensive and accurate Directory of companies and executives in the USA biotechnology industry.

January 2012 -

USA Medical Devices & Diagnostics Companies 2012-2013

US$ 200.00

PDF version is dispatched within twenty-four hours after the purchase. The most comprehensive and accurate Directory of companies and executives in the USA medical devices & diagnostics industry.

January 2012 -

Innovative Technologies And Their Impact on the US Diagnostics Market

US$ 3,880.00

The next ten years will be marked by significant technological developments in health care and biotechnology, which will drastically change the assumptions ... The report explores the impact of the most significant technological developments of the next ten years and their impact on the U.S. in vitro diagnostics ...

January 2012 85 pages

Analyzing the Mining Industry in the United States

US$ 350.00

The United States mining industry is an important ... process in order to remain global leaders. The United States produces a wide variety of commodities from gold to ... R'search’s report – Analyzing the Mining Industry in the United States - explains the historical lineage of mining as instincts to search ...

January 2012 200 pages

US Mining Industry – Porter’s Five Forces Strategy Analysis

US$ 200.00

The United States mining industry is an important contributor to ... indirectly. Aruvian's R'search analyzes The US Mining Industry in Michael Porter’s Five Forces Analysis. It uses concepts ... competitive intensity and therefore attractiveness of a market. Porter referred to these forces as the microenvironment, to ...

January 2012 35 pages

Chemical Industry in Canada

US$ 350.00

... for Canadian chemical producers. Aruvian's R'search analyzes the Canadian chemical industry in its new report Chemical Industry in Canada. The report ... researches the characteristics of the Canadian chemical industry ...

January 2012 50 pages

Analyzing the Market for Nuclear Reactor Coolant Pumps in Canada

US$ 500.00

... offering Analyzing the Market for Nuclear Reactor Coolant Pumps in Canada . The report is a complete coverage of the nuclear reactor coolant pumps in Canada and analyzes this strategic market for ...

January 2012 165 pages

Analyzing the Market for Nuclear Reactor Coolant Pumps in the US

US$ 500.00

... percent of the electricity in the United States. With the US being the biggest supplier of commercial nuclear power in the world, the demand ... itself. Aruvians Rsearch analyzes the US market for nuclear reactor coolant pumps in its research offering Analyzing the Market for Nuclear Reactor Coolant Pumps in ...

January 2012 170 pages

ARQULE - Positive Data in HCC is an Add-On!

US$ 140.00

Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in ... raises expectations and the efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead indication – NSCLC ... read our report released on 19th January, 2012 on ArQule titled “Positive Data in HCC is an Add-On!”

January 2012 3 pages

AstraZeneca, Bristol-Myers Squibb - Complete Response for Dapagliflozin

US$ 90.00

Today BMY and AstraZeneca jointly announced the receipt of complete response letter from FDA for its first-in-class Dapagliflozin ( ...

January 2012 2 pages

REGENERON – Eylea Sales Add a Sparkle to The Eye!

US$ 120.00

... and Avastin (off-label), Regeneron (REGN) overwhelmed all concerns of a “weak launch” of Eylea (VEGF Trap-Eye, L, ... Bill” model! Uptake at this pace should entitle Eylea to capture…. Moreover, CEO’s optimism around REGN’s ... released on 11th January, 2012 on Regeneron titled “Eylea Sales Add a Sparkle to The Eye!”

January 2012 6 pages

HCV_M&A - “Mirror, Mirror on the Wall (HCV) – Who is the Fairest of them all!”

US$ 140.00

... details, please read our report released on 10th January, 2012 on HCV_M&A titled “Mirror, Mirror on the Wall (HCV) – Who is the Fairest of them all ...

January 2012 6 pages

REGENERON - Eylea’s Litigation Settlement = Good Start to 2012!

US$ 90.00

Regeneron (REGN) settled its patent litigation with Genentech (Roche) over Eylea (VEGF Trap-Eye, L, partnered ... payments to Roche -$60m when cumulative US sales of Eylea reach $400m + will pay royalties of 4.75% on ... 6th January, 2012 on Regeneron titled “Eylea’s Litigation Settlement = Good Start to 2012!”

January 2012 6 pages

AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!

US$ 90.00

Data from TIVO-1, PhIII study (head-to-head study with ONXX’s Nexavar) of Tivozanib (formerly AV- ... details, please read our report released on 4th January, 2012 on AVEO pharma titled “PhIII, TIVO-1 Data and Reaction - No Surprise!”

January 2012 3 pages

Filters

Search

Categories

4,016
3,705
2,886
2,530
2,008
1,590
1,200
1,066
1,056
1,005
871
857
778
738
603
553
550
489
473
437
416
372
348
341
306
275
270
270
264
258
256
200
186
184
173
142
114
105
103
91
87
80
79
74
73
62
60
59
57
52
52
49
47
46
44
41
40
36
35
35
33
31
31
29
28
26
25
25
24
22
22
21
20
20
19
17
16
15
15
14
12
12
11
11
11
11
10
10
10
10
9
9
9
9
9
8
8
8
8
8
7
7
7
7
7
6
6
6
6
6
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
7
6
5
1
8
2
2
1
1
5
4
2
12
2
16
1
1
8
1
1
74
32
2
2
24
3
36
39
3
1
5
11
7
6
6
6
6
5
4
4
4
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
434
6
24
2
27
7
3
8
2
1
8
1
8
74
16
24
3
1
8
7
1
2,760
2
1
8
5
19
14
12
11
11
10
9
9
8
8
7
6
6
5
4
4
4
4
4
4
3
3
2
2
2
2
1
1
1
4
3
2
4
7
5
4
3
2
2
2
2
2
1
8
1
1
15
3
9
1
5
6
4
3
1
7
3
2
1
1
3
5
3
1
1
15
5
8
103
5
7
2
2
1
1
3
3
1
5
3
2
3,972
513
481
405
331
269
206
196
187
117
110
80
79
64
61
55
52
51
50
46
45
44
42
39
39
33
29
27
27
24
21
16
16
12
12
12
11
11
10
10
10
9
9
9
9
9
9
8
8
8
8
8
8
8
7
7
7
7
7
7
6
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
1
7
10
4
3
3
3
2
2
1
1
2
107
9
2
5
13
4
12
3
120
5
4
9
7
5
4
3
3
179
86
10
3
4
3
3
2
1
2
4
1
11
4
1
14
10
8
6
3
2
1
1
1
58
13
671
144
140
78
73
65
61
42
38
37
36
35
34
27
24
23
17
16
16
15
14
12
11
10
10
7
7
5
5
4
4
4
3
3
1
1
10
8
2
70
1
1
9
6
2
2
6
17
1
1
2
108
3
2
8
6
5
4
4
1
4
24
1
8
6
1
1
3
2
1
2
7
2
4
6
4
1
1
8
3
2
1
2
2
9
63
258
4
1
3
1
5
1
14
40
8
55
2
2
3
3
7
3
114
29
5
2
9,026
15
3
48
245
83
2
101
1
4
22
39
446
16
24
655
26
145
171
29
80
4
4
44
26
209
4
50
46
28
17
7
1
19
7
1
1
1
16
72
4
5
2
98
12

Publishers

15,092
13,573
7,070
881
236
126
120
106
19
14
6,959
1,146
1,034
4
234
117
160
3
12
32
2
646
7,395
93
1
4,194
391
5,213
1
11
1
10,002
53
2
1
2
2
6
10
8
618
2
3
5
18
57
4,997
1
9
1,519
2
175
2
7
5
96
417
2
224
2
180
51
196
13
5,936
422
1,029
2
2
15
4
19
6
49
741
27
4
11
125
17
158
3,899
2
217
8
53
13
161
158
2
17
17
27
27
80
49
154
6
3

Regions

11,703
4,264
1,040
887
858
830
822
822
787
465
412
358
348
311
211
80
44
43
43
15
13
6
3
1
1
1
1
751
20,260
301
351
2
1
51,015

Price

—

Date

—

Pages

—

Offers

417
1